Full Title
Expanded Access Use of L-MTP-PE for the Treatment of OsteosarcomaPurpose
This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system to kill cancer cells. L-MTP-PE is given intravenously (by vein).
Protocol
20-324
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04571229
ClinicalTrials.gov